Last reviewed · How we verify
Champix — Competitive Intelligence Brief
marketed
Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4, Neuronal acetylcholine receptor; alpha4/beta2
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Champix (Champix) — The Queen Elizabeth Hospital.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Champix TARGET | Champix | The Queen Elizabeth Hospital | marketed | Neuronal acetylcholine receptor subunit alpha-7, Neuronal acetylcholine receptor; alpha3/beta4, Neuronal acetylcholine receptor; alpha4/beta2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
Cite this brief
Drug Landscape (2026). Champix — Competitive Intelligence Brief. https://druglandscape.com/ci/champix. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab